

ACE-031 1mg
€60.00

ACE-031 1mg
€60.00
- Description
- Benefits
- Risks
- Additional information
- Research
Description
ACE-031 is a recombinant fusion protein developed for advanced research into muscle growth regulation and myostatin signalling pathways. It functions as a decoy receptor, binding to ligands such as myostatin (GDF-8) and activins, preventing them from interacting with their natural receptors.
In laboratory research settings, ACE-031 is widely studied for its role in modulating growth differentiation factors, particularly within the TGF-beta signalling pathway, which plays a central role in regulating muscle development and tissue growth.
Due to its mechanism of action, ACE-031 has become a key compound in research peptide studies across Ireland and Europe, especially in areas involving:
- Myostatin inhibition models
- Muscle growth signalling pathways
- ActRIIB receptor binding studies
- Growth factor regulation research
This product is supplied as a high-purity research peptide, intended strictly for scientific and laboratory use.
Disclaimer: This product is strictly for research purposes only and is not for human consumption.
Technical Information – ACE-031
| Specification | Details |
|---|---|
| Product Name | ACE-031 |
| Compound Type | Recombinant fusion protein |
| Functional Class | Myostatin pathway inhibitor |
| Mechanism of Action | ActRIIB receptor decoy binding |
| Molecular Targets | Myostatin (GDF-8), activins |
| Biological Pathway | TGF-beta signalling pathway |
| Format | Lyophilised powder |
| Purity | Research-grade (high purity) |
| Storage | Refrigerated (2–8°C, protected from light) |
| Application | Laboratory research use only |
* Images for illustration purposes only
Further Refrences: PubChem Entry
Researched Benefits & Focus Areas – ACE-031
1. Myostatin Inhibition & Muscle Growth Regulation
ACE-031 has been studied for its ability to inhibit myostatin activity:
- Investigated for reducing inhibitory signals on muscle growth
- Supports research into lean tissue development pathways
- Explored in muscle hypertrophy models
Reference basis: Derived from preclinical research into myostatin inhibition and ActRIIB receptor binding, widely documented in molecular biology and endocrinology literature.
2. ActRIIB Receptor Binding Mechanism
ACE-031 acts as a decoy receptor targeting ActRIIB:
- Blocks ligand-receptor signalling interactions
- Alters growth factor communication pathways
- Enables study of receptor-level signalling modulation
Reference basis: Supported by biochemical and receptor-binding studies analysing activin receptor interactions and ligand sequestration.
3. Muscle Wasting & Degenerative Condition Models
Research has explored ACE-031 in:
- Muscle atrophy and wasting models
- Cachexia-related experimental studies
- Regenerative biology research
Reference basis: Based on early-stage therapeutic research into muscle degeneration and protein regulation pathways.
4. TGF-Beta & Growth Factor Pathway Modulation
ACE-031 interacts with broader signalling systems:
- Influences TGF-beta superfamily pathways
- Modulates activins and growth differentiation factors
- Impacts biological growth regulation mechanisms
Reference basis: Mechanistic insights supported by biochemical pathway databases (e.g. PubChem) and experimental signalling studies.
Disclaimer: These are research-based findings only. This product is not intended for human use or consumption.
Researched Risks & Considerations – ACE-031
1. Off-Target Ligand Binding
ACE-031 may interact with multiple signalling molecules:
- Potential to affect non-target biological pathways
- May influence broader growth factor systems
Reference basis: Documented in receptor-binding studies highlighting cross-reactivity within the TGF-beta signalling family.
2. Vascular & Structural Effects (Preclinical Data)
Some studies have indicated:
- Possible effects on vascular integrity
- Influence on angiogenesis and tissue structure
Reference basis: Observations from preclinical and early clinical research involving ACE-031 analogues and related compounds.
3. Disruption of Natural Growth Regulation
Blocking myostatin may result in:
- Imbalance in muscle growth regulation
- Alteration of homeostatic biological processes
Reference basis: Based on endocrinology research examining myostatin’s role in regulating muscle development.
4. Limited Long-Term Human Data
- Research remains largely preclinical
- Lack of validated long-term human studies
- Unknown long-term systemic effects
Reference basis: Reflects the current early-stage status of ACE-031 research and limited clinical data availability.
Disclaimer: These risks are based on available research data only. This product is strictly a research peptide and not for human consumption.
Additional information
| Weight | 23 kg |
|---|---|
| Dimensions | 12 × 23 × 56 cm |
| Quantity | 1 Vial, 1 Kit (10 Vials) |